Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee

Denis Wakefield*, Peter McCluskey, Gerhild Wildner, Stephan Thurau, Gregory Carr, Soon Phaik Chee, John Forrester, Andrew Dick, Bernard Hudson, Susan Lightman, Justine Smith, Ilknur Tugal-Tutkun, on behalf of the pre-treatment assessment Review panel

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)

11 Citations (Scopus)
166 Downloads (Pure)

Abstract

Aim To outline recommendations from an expert committee on the assessment and investigation of patients with severe inflammatory eye disease commencing immunosuppressive and/or biologic therapy.

Method The approach to assessment is based on the clinical experience of an expert committee and a review of the literature with regard to corticosteroids, immunosuppressive drug and biologic therapy and other adjunct therapy in the management of patients with severe sight-threatening inflammatory eye disease.

Conclusion We recommend a careful assessment and consultative approach by ophthalmologists or physicians experienced in the use of immunosuppressive agents for all patients commencing immunosuppressive and/or biologic therapy for sight threatening inflammatory eye disease with the aim of preventing infection, cardiovascular, metabolic and bone disease and reducing iatrogenic side effects.
Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalAutoimmunity Reviews
Volume16
Issue number3
Early online date27 Jan 2017
DOIs
Publication statusPublished - 1 Mar 2017

    Fingerprint

Keywords

  • Biologicals
  • Evaluation
  • Immunosuppression
  • Therapy
  • Uveitis

Cite this

Wakefield, D., McCluskey, P., Wildner, G., Thurau, S., Carr, G., Chee, S. P., Forrester, J., Dick, A., Hudson, B., Lightman, S., Smith, J., Tugal-Tutkun, I., & on behalf of the pre-treatment assessment Review panel (2017). Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmunity Reviews, 16(3), 213-222. https://doi.org/10.1016/j.autrev.2017.01.003